Effect of HIPEC on Peritoneal Recurrence in Peritoneal Metastasis Treated With Cytoreductive Surgery: A Systematic Review

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Dec 20

PMID 34926311

Citations 11

Authors

Daniel Ren Yi Yap

Jolene Si Min Wong

Qiu Xuan Tan

Joey Wee-Shan Tan

Claramae Shulyn Chia

Chin-Ann Johnny Ong

Affiliations

Soon will be listed here.

Abstract

Background: Peritoneal metastasis (PM) is a late-stage manifestation of intra-abdominal malignancies. The current standard of care indicates that cure can only be achieved with cytoreductive surgery (CRS) which is often indicated with concurrent adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC). However, the utility of HIPEC within subsets of PM is not fully understood. We seek to compare the effectiveness of HIPEC in improving peritoneal recurrence rates in PM of different origins.

Methods: We conducted a systematic review of trials on the PubMed, EMBASE, and Cochrane databases, last searched in August 2021. Biases were assessed using the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials as well as the Methodological Index for Non-Randomized Studies (MINORS) framework.

Results: 7 gastric PM studies, 3 ovarian PM studies, and 3 colorectal PM studies were included. Recurrence-free survival was improved in the HIPEC + CRS cohort in 5 gastric trials but only 1 ovarian trial and none of colorectal origin.

Discussion: Our findings indicate decent effectiveness of HIPEC in gastric PM, but limited utility in ovarian and colorectal PM. Limitations in the current literature are attributed to the paucity of data available, a lack of homogeneity and consideration of novel and personalised treatment regimens. We implore for further studies to be conducted with a focus on patient selection and stratification, and suggest a reframing of approach towards modern molecular and targeted therapeutic options in future studies of HIPEC.

Systematic Review Registration: https://www.researchregistry.com/browse-the-registry#registryofsystematicreviewsmeta-analyses/registryofsystematicreviewsmeta-analysesdetails/60c1ffff0c1b78001e8efbe3/, identifier reviewregistry1166.

Citing Articles

Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy applications in upper and lower gastrointestinal cancer, a review.

Drittone D, Schipilliti F, Arrivi G, Mazzuca F Oncol Rev. 2024; 18:1496141.

PMID: 39659741 PMC: 11628282. DOI: 10.3389/or.2024.1496141.

Non-Coding RNAs in Peritoneal Carcinomatosis: From Bench to Bedside.

Bohosova J, Ashraf N, Slaby O, Calin G Cancers (Basel). 2024; 16(17).

PMID: 39272819 PMC: 11394633. DOI: 10.3390/cancers16172961.

Impact of hyperthermic intraperitoneal chemotherapy on gastric cancer survival: Peritoneal metastasis and cytology perspectives.

Methasate A, Parakonthun T, Intralawan T, Nampoolsuksan C, Swangsri J World J Clin Oncol. 2024; 15(7):840-847.

PMID: 39071459 PMC: 11271738. DOI: 10.5306/wjco.v15.i7.840.

Enhanced anti-tumor efficacy with multi-transgene armed mesenchymal stem cells for treating peritoneal carcinomatosis.

Ho Y, Woo J, Loke K, Deng L, Too H J Transl Med. 2024; 22(1):463.

PMID: 38750559 PMC: 11097589. DOI: 10.1186/s12967-024-05278-5.

A prospective Canadian gastroesophageal cancer database: What have we learned?.

Purich K, Skubleny D, Ghosh S, Bedard E, Stewart K, Johnson S Can J Surg. 2023; 66(4):E422-E431.

PMID: 37553256 PMC: 10414783. DOI: 10.1503/cjs.005122.

References

Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M . Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):256-266. DOI: 10.1016/S1470-2045(20)30599-4. View

Lotti M, Capponi M, Piazzalunga D, Poiasina E, Pisano M, Manfredi R . Laparoscopic HIPEC: A bridge between open and closed-techniques. J Minim Access Surg. 2016; 12(1):86-9. PMC: 4746985. DOI: 10.4103/0972-9941.158965. View

Glehen O, Cotte E, Kusamura S, Deraco M, Baratti D, Passot G . Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008; 98(4):242-6. DOI: 10.1002/jso.21061. View

McMullen J, Selleck M, Wall N, Senthil M . Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. Oncotarget. 2017; 8(26):43481-43490. PMC: 5522163. DOI: 10.18632/oncotarget.16480. View

Yap D, Wong J, Tan Q, Tan J, Chia C, Ong C . Effect of HIPEC on Peritoneal Recurrence in Peritoneal Metastasis Treated With Cytoreductive Surgery: A Systematic Review. Front Oncol. 2021; 11:795390. PMC: 8678115. DOI: 10.3389/fonc.2021.795390. View

Ong C, Shannon N, Mueller S, Lek S, Qiu X, Chong F . A three gene immunohistochemical panel serves as an adjunct to clinical staging of patients with head and neck cancer. Oncotarget. 2017; 8(45):79556-79566. PMC: 5668068. DOI: 10.18632/oncotarget.18568. View

Fagotti A, Costantini B, Gallotta V, Cianci S, Ronsini C, Petrillo M . Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes. J Minim Invasive Gynecol. 2014; 22(3):428-32. DOI: 10.1016/j.jmig.2014.11.008. View

Gonzalez-Moreno S, Gonzalez-Bayon L, Ortega-Perez G . Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol. 2010; 2(2):68-75. PMC: 2999165. DOI: 10.4251/wjgo.v2.i2.68. View

Goodman M, McPartland S, Detelich D, Saif M . Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016; 7(1):45-57. PMC: 4754301. DOI: 10.3978/j.issn.2078-6891.2015.111. View

10.

Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T . Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1999; 85(3):529-34. View

11.

Yang X, Huang C, Suo T, Mei L, Yang G, Cheng F . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011; 18(6):1575-81. PMC: 3087875. DOI: 10.1245/s10434-011-1631-5. View

12.

Bonnot P, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B . Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. J Clin Oncol. 2019; 37(23):2028-2040. DOI: 10.1200/JCO.18.01688. View

13.

Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T . Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer. 1988; 61(2):232-7. DOI: 10.1002/1097-0142(19880115)61:2<232::aid-cncr2820610205>3.0.co;2-u. View

14.

Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E . Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2014; 22(5):1570-5. DOI: 10.1245/s10434-014-4157-9. View

15.

Harter P, Reuss A, Sehouli J, Chiva L, du Bois A . Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al. Int J Gynecol Cancer. 2017; 27(2):246-247. DOI: 10.1097/IGC.0000000000000864. View

16.

Neuwirth M, Alexander H, Karakousis G . Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. J Gastrointest Oncol. 2016; 7(1):18-28. PMC: 4754315. DOI: 10.3978/j.issn.2078-6891.2015.106. View

17.

Mi D, Li Z, Yang K, Cao N, Lethaby A, Tian J . Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. Int J Hyperthermia. 2013; 29(2):156-67. DOI: 10.3109/02656736.2013.768359. View

18.

Goere D, Glehen O, Quenet F, Guilloit J, Bereder J, Lorimier G . Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020; 21(9):1147-1154. DOI: 10.1016/S1470-2045(20)30322-3. View

19.

Ghirardi V, Ronsini C, Trozzi R, Di Ilio C, Di Giorgio A, Cianci S . Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience. Cancer. 2020; 126(24):5256-5262. DOI: 10.1002/cncr.33167. View

20.

Hamazoe R, Maeta M, Kaibara N . Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer. 1994; 73(8):2048-52. DOI: 10.1002/1097-0142(19940415)73:8<2048::aid-cncr2820730806>3.0.co;2-q. View